Side-by-side · Research reference
5-Amino-1MQvsKPV
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongDraft8/38 cited
BAnimal-StrongDraft13/39 cited
5-Amino-1MQ
NNMT inhibitor · Methylation / SAM modulation
Oral · Once daily fasted
KPV
α-MSH C-terminal · Anti-inflammatory
SQ / oral / topical · Local · Daily or 2-3×/week
01Mechanism of Action
Parameter
5-Amino-1MQ
KPV
Primary target
Nicotinamide N-methyltransferase (NNMT)Neelakantan 2018
Intracellular targets bypassing melanocortin receptors (proposed)Dalle-Pang 2024
Pathway
NNMT inhibition → preserved cellular SAM + NAD⁺ → restored methylation balance + ↑ thermogenic gene expressionNeelakantan 2018
NF-κB inhibition + cytokine modulation (TNF-α, IL-1β, IL-6) → reduced inflammationDalle-Pang 2024
Downstream effect
Reversal of HFD-induced obesity in murine models; improved metabolic profileNeelakantan 2018
Anti-inflammatory action without α-MSH pigmentation effects; gut barrier protectionDalle-Pang 2024
Feedback intact?
—
No melanocortin receptor binding
Origin
Selective small-molecule inhibitor designed in academic medicinal chemistry programsNeelakantan 2018
Synthetic tripeptide; the C-terminal Lys-Pro-Val residues of α-MSH (residues 11-13)Dalle-Pang 2024
Antibody development
—
—
02Dosage Protocols
Parameter
5-Amino-1MQ
KPV
Standard dose
100–200 mg / day oralNeelakantan 2018
Anecdotal community range; murine doses scaled.
200–500 mcg / day SQ or oralDalle-Pang 2024
Frequency
Once daily, fasted
Daily or 2–3× per week
Lower / starter dose
50 mg / day
100 mcg / day
Evidence basis
Animal-strong; no human RCT dataNeelakantan 2018
Animal-strong + emerging clinical data in IBDDalle-Pang 2024
Duration
8–12 weeks per cycle
4–8 weeks per cycle
Form
Oral capsule
—
Timing
Morning fasted preferred
No specific time; often taken with / before meals (oral)
Half-life
Hours (estimated; no human PK published)
Hours (estimated; rapid tissue uptake)
Reconstitution
—
Bacteriostatic water (SQ form)
04Side Effects & Safety
Parameter
5-Amino-1MQ
KPV
GI symptoms
Mild nausea (anecdotal)
Rare nausea (oral form)
Methylation disruption
Theoretical risk if NNMT is over-inhibited (B vitamin metabolism)
—
Long-term safety
Unknown — no human trials
Limited human data
Cancer risk
Unclear — NNMT also studied in oncology contexts
—
Pregnancy / OB
Avoid
Avoid — insufficient data
Drug interactions
Theoretical with niacin / B-vitamin supplements
—
Injection site reaction
—
Mild irritation
Absolute Contraindications
5-Amino-1MQ
- ·Pregnancy / breastfeeding
- ·Active malignancy
KPV
- ·Pregnancy / breastfeeding
Relative Contraindications
5-Amino-1MQ
- ·Methylation-sensitive conditions (MTHFR mutation)
- ·Concurrent niacin / NAD+ precursor supplementation (theoretical interference)
KPV
- ·Active autoimmune disease (theoretical)
05Administration Protocol
Parameter
5-Amino-1MQ
KPV
1. Form
Oral capsule. No injection.
Add 1 mL bacteriostatic water to vial per labelling.
2. Administration
Take with water, fasted preferred.
SQ injection (acute), oral capsule (chronic / gut), topical for skin indications.
3. Timing
Morning fasted.
Morning preferred; oral form taken with / before meals.
4. Storage
Room temp ≤25 °C, dry place.
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
5. Caveat
Monitor B-vitamin status with chronic use.
29–31G insulin syringe (SQ form).
06Stack Synergy
5-Amino-1MQ
— no documented stacks
KPV
+ BPC-157
StrongKPV (NF-κB inhibition, cytokine reduction) + BPC-157 (VEGF-driven angiogenesis, tissue regeneration) form the classic gut-healing stack. KPV reduces inflammatory drive; BPC-157 promotes mucosal repair. Anecdotally favoured for IBD, ulcerative colitis, and post-surgical gut recovery.
- KPV
- 200–500 mcg oral · daily
- BPC-157
- 250–500 mcg oral or SQ · daily
- Primary benefit
- Combined anti-inflammation + mucosal repair for gut conditions